The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Design, power, and interpretation of studies in the standard murine model of ALS
Abstract
Identification of SOD1 as the mutated protein in a significant subset of familial amyotrophic lateral sclerosis (FALS) cases has led to the generation of transgenic rodent models of autosomal dominant SOD1 FALS. Mice carrying 23 copies of the human SOD1(G93A) transgene are considered the standard model for FALS and ALS therapeutic studies. To date, there have been at least 50 publications describing therapeutic agents that extend the lifespan of this mouse. However, no therapeutic agent besides riluzole has shown corresponding clinical efficacy. We used computer modeling and statistical analysis of 5429 SOD1(G93A) mice from our efficacy studies to quantify the impact of several critical confounding biological variables that must be appreciated and should be controlled for when designing and interpreting efficacy studies. Having identified the most critical of these biological variables, we subsequently instituted parameters for optimal study design in the SOD1(G93A) mouse model. We retested several compounds reported in major animal studies (minocycline, creatine, celecoxib, sodium phenylbutyrate, ceftriaxone, WHI-P131, thalidomide, and riluzole) using this optimal study design and found no survival benefit in the SOD1(G93A) mouse for any compounds (including riluzole) administered by their previously reported routes and doses. The presence of these uncontrolled confounding variables in the screening system, and the failure of these several drugs to demonstrate efficacy in adequately designed and powered repeat studies, leads us to conclude that the majority of published effects are most likely measurements of noise in the distribution of survival means as opposed to actual drug effect. We recommend a minimum study design for this mouse model to best address and manage this inherent noise and to facilitate more significant and reproducible results among all laboratories employing the SOD1(G93A) mouse.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inappropriate data cleaning has the potential to bias study outcomes [53]; providing the reasoning for removing data points enables the distinction to be made between responsible data cleaning and data manipulation.”
From Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0 (2020) · cites this paper as [53]
In the citing paper
“The ALS Therapy Development Institute rigorously retested more than 100 drug candidates in the superoxide dismutase 1 (SOD1) mouse model, and they were unable to replicate many of the previously reported preclinical efficacy findings85.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [85]
In the citing paper
“Lack of reproducibility in preclinical models and lack of translation from preclinical efficacy for drugs tested in the SOD1 mouse model to patients with ALS explain why the profiling of drug candidates in the SOD1 mouse model poorly translated into clinical efficacy85.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [85]
In the citing paper
“The reproducibility of preclinical results has been problematic in the field of amyotrophic lateral sclerosis (ALS).”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [85]
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
Sterne, J. A. C. (2001) · BMJ · doi:10.1136/bmj.322.7280.226 · Cited by 1,466
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub3 · Cited by 1,123
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V. O., Li, M., Sarang, S. S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,069
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Gurney, M. E., Cutting, F. B., Zhai, P., Doble, A., Taylor, C. P., Andrus, P. K., & Hall, E. D. (1996) · Annals of Neurology · doi:10.1002/ana.410390203 · Cited by 647
Research works printed but not linked: 3
- Chen R., 2000, J Med, 31, 21
- Andries M., 2006, Neurobiol Dis.
- Ramesh T. M., Buradagunta S., Thompson K., et al. Analysis of critical parameters for preclinical drug screening in the SOD1 G93A mouse model for amyotrophic lateral sclerosis., Abstract at the 13 th International Symposium on ALS/MND; November, 2002; Melbourne
Cited by
Sorted by citations
Items 401–500 of 503
Remmers, N. A., Cox, J. L., Grunkemeyer, J. A., Aravind, S., Arkfeld, C. K., Hollingsworth, M. A., & Carlson, M. A. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/267112 · Cited by 3
Animal Models of Alzheimer's Disease
Bharadwaj, P. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch10 · Cited by 3
Measuring the replicability of our own research
Brown, R. E. (2024) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2024.110111 · Cited by 5
Does Amyotrophic Lateral Sclerosis (ALS) Have Metabolic Causes from Human Evolution?
Spedding, M. (2025) · Cells · doi:10.3390/cells14211734 · Cited by 2
Assessing the Effect of Riluzole on Motor Unit Discharge Properties
Shandiz, E. E., Fernandes, G. L., Henkin, J. S., McCombe, P., Trajano, G. S., & Henderson, R. D. (2024) · Brain Sciences · doi:10.3390/brainsci14111053 · Cited by 2
Mueller, K. A., Suneby, E. G., Ferola, M. H., Moreno, A. J., Kidd, J. D., Thompson, K., Vieira, F. G., Valdez, G., & Hatzipetros, T. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106975 · Cited by 2
Self-citationAmyotrophic Lateral Sclerosis: An Introduction to Treatment and Trials
Martin, H. (2012) · InTech eBooks · doi:10.5772/34020 · Cited by 2
Learning from Principles of Evidence-Based Medicine to Optimize Nonclinical Research Practices
Lefevre, I. A., & Balice‐Gordon, R. J. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_276 · Cited by 3
Toward failure analyses in systems biology
Bhattacharya, S. K., Gomes, J., & Cebulla, C. M. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.83 · Cited by 2
Loan, J. J., Connolly, S. D., Haunschmidt, D. Z., Bell, S. B., Clarke, S. A., Kelly, J., Oswald, A. J., & Rae, V. (2012) · Biochemistry and Molecular Biology Education · Cited by 2
Diseases of Motor Neurons and Neuromuscular Junctions
Sontheimer, H. W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800244-5.00006-9 · Cited by 2
Fotinos, A., Zhu, Y., Mao, L. L. J., Atassi, N., Zhou, E., Ahmad, S., Guan, Y., Berry, J. D., Cudkowicz, M., & Wang, X. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_51 · Cited by 2
Winter, A. N. (2016) · Digital Commons - DU (University of Denver) · Cited by 2
Neuroinflammation in Neurological Disorders
Kira, J. (2013) · Advances in neurobiology · doi:10.1007/978-1-4614-8313-7_2 · Cited by 2
Genetic and pharmacologic analysis of the mechanisms of selenium toxicity in Caenorhabditis elegans
Morgan, K. L. (2008) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 2
What is the clinical significance of SOD1 mutations in amyotrophic lateral sclerosis?
Orrell, R. W. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.205575 · Cited by 2
mSOD1-NSG mice: a new in vivo model to test human T cells in ALSPreprint
Graber, D. J., Sentman, M.-L., Cook, W. J., & Sentman, C. L. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.27.461982 · Cited by 2
Balas, E. A. (2018) · Wiley eBooks · doi:10.1002/9781119225898.ch6 · Cited by 2
Festing, M. F. W. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527695881.ch3 · Cited by 2
Bi, Y., Yan, X., Yacipi, N., Duan, W., Li, C., Thompson, M. J., Shan, Z. J., & Bi, L. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.02.514252 · Cited by 2
The ALSUntangled Group (2011) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482968.2011.625168 · Cited by 1
Helal, M. M., Almosilhy, N. A., Abo‐elnour, D. E., Jaffal, R., Allam, E. G., Almosilhy, M. A., Batarseh, S. F., & Meshref, M. M. (2026) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2026.2627901 · Cited by 2
Maiväli, Ü. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-418689-7.00006-5 · Cited by 1
Stem Cells for Neuro-regeneration: State of the Art
Wagih, A. (2015) · American Journal of Bioscience and Bioengineering · doi:10.11648/j.bio.s.2015030401.19 · Cited by 1
Overview of Mouse Models for Psychiatric and Neurologic Disorders
Lindner, M. D., & McArthur, R. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-369497-3.10031-7 · Cited by 1
Bushby, K. M. D. (2015) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-150096 · Cited by 1
Future of Regulatory Safety Assessments
Bode, G., & Starck-Lantova, P. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_71 · Cited by 1
Preclinical Experimental Therapeutics
Bates, G. P., & Landles, C. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199929146.003.0016 · Cited by 1
New forms of checks and balances are needed to improve research integrity
Iorns, E. J., & Chong, C. (2014) · F1000Research · doi:10.12688/f1000research.3980 · Cited by 1
From Calcium Channels to New Therapeutics
McDonough, S. I. (2022) · Springer eBooks · doi:10.1007/978-3-031-08881-0_27 · Cited by 1
McKinnon, S., Qiang, Z., Keerie, A. F. A., Wells, T. R., Shaw, P. J., Alix, J. J. P., & Mead, R. J. (2025) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2024.2448540 · Cited by 1
Mackay‐Sim, A. (2012) · Elsevier eBooks · doi:10.1533/9780857096074.3.309 · Cited by 1
Do We Need a Science of Science?
Maiväli, Ü. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-418689-7.00001-6 · Cited by 1
Lost and Found in Behavioral Informatics
Haendel, M. A., & Chesler, E. J. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-388408-4.00001-0 · Cited by 1
DNA Editing for Amyotrophic Lateral Sclerosis: Leading Off First Base
Cunningham, T. J., Fisher, E., Fratta, P., & Gilthorpe, J. D. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.29087.tcu · Cited by 1
Regenerative Medicine of Neural Tissues
Stocum, D. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-384860-4.00011-3 · Cited by 4
Neurotrophic Therapy for ALS/MND
Fowler, M., Shepheard, S. R., & Rogers, M. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_34 · Cited by 1
The Solution to Science's Replication CrisisPreprint
Knuteson, B. (2016) · SSRN Electronic Journal · doi:10.2139/ssrn.2835131 · Cited by 2
Neves, K., Carneiro, C. F. D., Wasilewska‐Sampaio, A. P., Abreu, M., Valério‐Gomes, B., Tan, P. B., & Amaral, O. B. (2020) · MetArXiv (OSF Preprints) · doi:10.31222/osf.io/njs6k · Cited by 1
Graber, D. J., & Hickey, W. F. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1071-7_26 · Cited by 1
Ethics review of animal research
Olsson, I. A. S., Olsson, S., Sandøe, P., Hawkins, P., & Jennings, M. (2024) · Wiley eBooks · doi:10.1002/9781119555278.ch18 · Cited by 1
Translational neuroscience requires better design and analysis of preclinical studiesPreprint
Lazic, S. E. (2012) · Nature Precedings · doi:10.1038/npre.2012.6987.1 · Cited by 1
The Role of Caspase-6 in Amyotrophic Lateral Sclerosis
Mitchem, M. R. (2014) · Figshare · doi:10.25419/rcsi.10819340
Pseudoreplication invalidates the results of many neuroscientific studies
Lazic, S. E. (2010) · Oxford University Research Archive (ORA) (University of Oxford)
Alterations in the myogenic capacity of satellite cells in a mouse model of ALS
English, S. A., Gupta, S., Clermont, D., Chen, D., Mázala, D. A. G., & Chin, E. R. (2012) · The FASEB Journal · doi:10.1096/fasebj.26.1_supplement.1078.28
Changing the attitudes of sex studies in science
Harris, A. L. (2015) · Surgery · doi:10.1016/j.surg.2014.12.018
Patterson, M. C. (2011) · Neurology · doi:10.1212/wnl.0b013e3182377e6f
Li, J., & Rutkove, S. B. (2013) · Journal of Physics Conference Series · doi:10.1088/1742-6596/434/1/012021
Mutant Superoxide Dismutase-1-caused pathogenesis in Amyotrophic Lateral Sclerosis
Bergemalm, D. (2010) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Kim, H. J. (2014) · eScholarship (California Digital Library)
Gene Therapy for Motor Neuron Disease
Boulis, N. M. (2011)
Govind, V. (2016) · Contemporary clinical neuroscience · doi:10.1007/978-3-319-33555-1_7
Electrophysiological biomarkers for the study of new therapeutic strategies for motoneuron disease
Mancuso, R. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
The role of ALS associated genes and c-Jun in neurodegeneration
Acosta‐Saltos, A. (2016) · UCL Discovery (University College London)
Morgan-Jack, B. R. (2013) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/44663
Future of Regulatory Safety Assessments
Bode, G., & Starck-Lantova, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-56637-5_71-1
Reduction of SOD Aggregation Using In Vitro and In Vivo ALS Models
’Shea, J. J. (2014)
The Solution to Science's Replication CrisisPreprint
Knuteson, B. (2016) · RePEc: Research Papers in Economics · doi:10.48550/arxiv.1609.03223
Intervju med biblioteksveteran Ragnar Hermansson, Färgelanda
Ljungcrantz, K. (1984) · Borås Academic Digital Archive (University of Borås)
Neurotrophic Therapy for ALS/MND
Fowler, M., Shepheard, S. R., & Rogers, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_34-1
Future of Regulatory Safety Assessments
Bode, G., & Starck-Lantova, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-56637-5_71-2
Balas, E. A. (2018) · doi:10.1002/9781119225898.ch3
SESSION 6A USE OF THE G93A SOD1 MOUSE IN THERAPEUTIC TESTING
(2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960802443214
Morgan, B. P. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739627914.793583462
(2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817443-2.00025-2
Park, S. H., Lee, S. B., Park, S., Kim, E. Y., Pizzol, D., Trott, M., Barnett, Y., Koyanagi, A., Jacob, L., Soysal, P., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2183732/v1
Reynolds, P. S. (2023) · Wiley eBooks · doi:10.1002/9781119800002.ch15
The Design and Statistical Analysis of Randomized Pre-clinical Experiments
Festing, M. F. W. (2023) · Springer eBooks · doi:10.1007/978-981-99-1284-1_28
Jiang, S., Li, M.-H., Dai, Q., Liu, X., Li, C., Jiao, H., Nie, H., Pan, H., & Xu, R. (2024) · Research Square · doi:10.21203/rs.3.rs-3939628/v1
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13829-4.00015-5
McKinnon, S., Qiang, Z., Keerie, A. F. A., Wells, T. R., Shaw, P. J., Alix, J. J. P., & Mead, R. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.09.593349
Fromholt, S., Lopez, A., Xu, G., Lü, Q., Wymer, J. P., & Borchelt, D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.01.616092
Future of Regulatory Safety Assessment
Bode, G., Starck-Lantova, P., & Kramer, P.-J. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_142
Lombardi, I., Ferrero, C., Vulcano, E., Rasà, D. M., Gelati, M., Campos, D. P., Carletti, R. M., de la Morena, S., Profico, D. C., Longobardi, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.18.624143
Rigor in Experimental Design in Nonregulated Preclinical Research in Neuroscience Drug Discovery
Steele, S., Bespalov, A., & Dequeker, E. M. C. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch6
Adipose-Derived Stem Cells for Amyotrophic Lateral Sclerosis
Gu, H., & Du, Y. (2025) · Neuromethods · doi:10.1007/978-1-0716-4783-7_5
Additional file 1 of The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12650470
Cox, L. M., Calcagno, N., Gauthier, C. D., Madore, C., Butovsky, O., & Weiner, H. L. (2022) · Figshare · doi:10.6084/m9.figshare.19343149
Cox, L. M., Calcagno, N., Gauthier, C. D., Madore, C., Butovsky, O., & Weiner, H. L. (2022) · Figshare · doi:10.6084/m9.figshare.19343143
Cox, L. M., Calcagno, N., Gauthier, C. D., Madore, C., Butovsky, O., & Weiner, H. L. (2022) · Figshare · doi:10.6084/m9.figshare.19343155
Additional file 4 of The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12650479
Cox, L. M., Calcagno, N., Gauthier, C. D., Madore, C., Butovsky, O., & Weiner, H. L. (2022) · Figshare · doi:10.6084/m9.figshare.19343152
Additional file 2 of The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12650473
Cox, L. M., Calcagno, N., Gauthier, C. D., Madore, C., Butovsky, O., & Weiner, H. L. (2022) · Figshare · doi:10.6084/m9.figshare.19343140
Cox, L. M., Calcagno, N., Gauthier, C. D., Madore, C., Butovsky, O., & Weiner, H. L. (2022) · Figshare · doi:10.6084/m9.figshare.19343146
Cox, L. M., Calcagno, N., Gauthier, C. D., Madore, C., Butovsky, O., & Weiner, H. L. (2022) · Figshare · doi:10.6084/m9.figshare.19343137
Wei‐LaPierre, L., Zhong, R., Rastelli, G., Ainbinder, A., Thome, T., Kim, K., Cort, T. A., Brandt, Z., Harris, E. N., Rua, M. T., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8825893/v1
Experimental Designs for Preclinical Neuroscience Experiments: Part 2—Blocking and Blocked Designs
Reynolds, P. S. (2026) · eNeuro · doi:10.1523/eneuro.0006-26.2026
Zhou, L., Li, M., Dai, Q., Liu, X., Li, C., Jiao, H., Pan, H., & Xu, R. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70946
Zebrafish swimming towards cures: a scalable NAM platform for drug discovery
Cutinho, V., & Williams, C. H. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104716
Estimating the replicability of Brazilian biomedical sciencePreprint
Initiative, T. B. R. (2026) · eLife · doi:10.7554/elife.111001
Estimating the replicability of Brazilian biomedical sciencePreprint
Initiative, T. B. R. (2026) · eLife · doi:10.7554/elife.111001.1
Reynolds, P. S., & Pearl, E. J. (2026) · Laboratory Animals · doi:10.1177/00236772261462343
Metadata
- Authors
- Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., Bostrom, A., Theodoss, J., Al‐Nakhala, B. M., Vieira, F. G., Ramasubbu, J., & Heywood, J. A.
- Affiliations
- Amyotrophic Lateral Sclerosis Therapy Development Institute (US)
- University of California, San Francisco (US)
- Corresponding author
- Scott, Sean
- Venue
- Amyotrophic Lateral Sclerosis
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 9
- Issue
- 1
- Pages
- 4-15
- ISSN
- 1471-180X (ISSN-L)
- 1748-2968
- OpenAlex
- W2087656730
- Cited by
- 504
- References
- 40
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 20 · 2023: 11 · 2022: 21 · 2021: 22 · 2020: 33 · 2019: 30 · 2018: 27 · 2017: 34 · 2016: 37 · 2015: 40 · 2014: 47 · 2013: 35 · 2012: 30
- FWCI
- 18.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Amyotrophic Lateral Sclerosis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- SOD1 G93A mice, familial ALS, research design, statistical power, confounding variables, survival analysis, drug efficacy, riluzole, minocycline, ceftriaxone, thalidomide, celecoxib, 4-phenylbutyric acid, creatine, statistical noise, reproducibility
- MeSH terms
- Superoxide Dismutase-1, Amyotrophic Lateral Sclerosis, Animals, Disease Models, Animal, Female, Male, Mice, Transgenic, Research Design, Species Specificity, Superoxide Dismutase, Survival Analysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
